Novel Nucleic Acid Sequencing Technology Development (R43/R44)

The summary for the Novel Nucleic Acid Sequencing Technology Development (R43/R44) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Novel Nucleic Acid Sequencing Technology Development (R43/R44): This Funding Opportunity Announcement (FOA) solicits R43/R44 SBIR grant applications from small businesses to develop novel technologies that will enable new approaches to DNA and direct RNA sequencing. Applicants may propose to develop novel complete sequencing systems, investigate challenges underlying key novel system components, or propose improvements of at least an order of magnitude improvement to existing systems. Exploration of methods other than those currently in use is highly encouraged. High-risk/high-payoff applications are appropriate to achieve the goals of this FOA.

Federal Grant Title:	Novel Nucleic Acid Sequencing Technology Development (R43/R44)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-HG-15-033
Type of Funding:	Grant
CFDA Numbers:	93.172
CFDA Descriptions:	Human Genome Research
Current Application Deadline:	Aug 27, 2017
Original Application Deadline:	Aug 27, 2017
Posted Date:	Aug 17, 2015
Creation Date:	Aug 17, 2015
Archive Date:	Sep 27, 2017
Total Program Funding:	$2,000,000
Maximum Federal Grant Award:	none
Minimum Federal Grant Award:	none
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following:
Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HG-15-033.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Addressing Health Inequities in Clinical Diagnostics (R41/R42 Clinical Trials Not Allowed); • Addressing Health Inequities in Clinical Diagnostics (R43/R44 Clinical Trials Not Allowed); • NHGRI Technology Development Coordinating Center (U24 Clinical Trial Not Allowed); • Solutions to Enable Regional Genomic Medicine eConsult Services (R41/R42 Clinical Trial Op...; • Research on the Impact of and Methods for Implementing Regional Genomic Medicine eConsult ...; • Near-Term Technology Development for Genome Sequencing - SBIR (R43/R44); • Near-Term Technology Development for Genome Sequencing - STTR (R41/R42); • Revolutionary Genome Sequencing Technologies - The $1000 Genome - SBIR (R43/R44)
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...